Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies

Cancer Treatment Reviews

Volumn 29, Issue 4, 2003, Pages 297-307

  Shannon, Aoife M ^a   Bouchier Hayes, David J ^a   Condron, Claire M ^a   Toomey, Deirdre ^a  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

Author keywords

Drug chemotherapeutic resistance; Hypoxia inducible genes; Hypoxia targeted therapy; Tumour hypoxia

Indexed keywords

ADENOVIRUS VECTOR; ALKYLATING AGENT; ANGIOSTATIN; ANTINEOPLASTIC AGENT; BLEOMYCIN; CHLORMETHINE; CISPLATIN; CYCLOOXYGENASE 2; CYCLOPHOSPHAMIDE; ERYTHROPOIETIN; ETOPOSIDE; FERRITIN; FIBROBLAST GROWTH FACTOR 3; GAMMA INTERFERON; GROWTH FACTOR; HEME OXYGENASE 1; HYPOXIA INDUCIBLE FACTOR 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MELPHALAN; NITRIC OXIDE SYNTHASE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; OXYGEN; PROTEOME; SOMATOMEDIN BINDING PROTEIN; TIRAPAZAMINE; TRANSCRIPTION FACTOR AP 1; TRANSFERRIN; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFICACY; DRUG HALF LIFE; GENE EXPRESSION; GENOME; HUMAN; HYPOXIA; MOUSE; NONHUMAN; OVARY CANCER; OXYGEN SUPPLY; PH; RAT; REVIEW; SOLID TUMOR; TUMOR CELL; TUMOR GROWTH; VASCULARIZATION; VIRAL GENE DELIVERY SYSTEM;

EID: 0042411985     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0305-7372(03)00003-3     Document Type: Article

References (124)

1. Berne RM, Levy MN. Transport of oxygen and carbon dioxide: tissue oxygenation. Physiology, 3rd edn., Missouri: Mosby-Year Book Inc, 1993; 590-598.
2. Ganong WF. Gas transport between the lungs and the tissues. Review of Medical Physiology, 19th edn. Stanford: Appleton and Lange, 1999; 635-639.
3. Höckel M, Vaupel P. Tumour Hypoxia: definitions and current clinical, biological, and molecular aspects. J Natl Cancer Inst 2001; 93: 266-276.
4. Harris AL. Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2002; 2: 38-47.
5. Vaupel P, Thews O, Hoeckel M. Treatment resistance of solid tumours: role of hypoxia and anemia. Med Oncol 2001; 18: 243-259.
6. Dachs GU, Tozer GM. Hypoxia modulated gene expression: angiogenesis, metastasis and therapeutic exploitation. Eur J Cancer 2000; 36: 1649-1660.
7. Höckel M, Vorndran B, Schlenger K, Baussmann E, Knapstein PG. Tumour oxygenation: a new predictive parameter in locally advanced cancer of the uterine cervix. Gynecol Oncol 1993; 52: 141-149.
8. Maxwell PH, Dachs GU, Gleadle JM, et al. Hypoxia-inducible factor-1 modulates gene expression in solid tumours and influences both angiogenesis and tumour growth. Proc Natl Acad Sci USA 1997; 94: 8104-8109.
9. Carmeliet P, Dor Y, Herbert J-M, et al. Role of HIF-1 in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 1998; 394: 485-490.
10. Wang GL, Semenza GL. Purification and characterisation of hypoxia-inducible factor-1. J Biol Chem 1995; 1: 1230-1237.
11. 2 tension. Proc Natl Acad Sci USA 1995; 92: 5510-5514.
12. Jiang BH, Rue E, Wang GL, Roe R, Semenza GL. Dimerization, DNA binding, and transactivation properties of HIF-1. J Biol Chem 1996; 271: 17771-17778.
13. Salceda S, Caro J. Hypoxia-inducible factor-1α (HIF-1α) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. J Biol Chem 1997; 272: 22642-22647.
14. Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999; 399: 271-275.
15. 2 sensing. Science 2001; 292: 464-468.
16. 2-regulated prolyl hydroxylation. Science 2001; 292: 468-472.
17. Huang LE, Arany Z, Livingston DM, Bunn HF. Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its α subunit. J Biol Chem 1996; 271: 32252-32259.
18. 2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 1998; 95: 7989-7992.
19. Srinivas V, Zhu X, Salceda S, Nakamura R, Caro J. Hypoxia-inducible factor-1α (HIF-1α) is a non-heme iron protein. Implications for oxygen sensing. J Biol Chem 1998; 273: 18019-18022.
20. Lu H, Forbes RA, Verma A. Hypoxia-inducible factor-1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis. J Biol Chem 2002; 277: 23111-23115.
21. Semenza GL, Nejfelt MK, Chi SM, Antonarakis SE. Hypoxia-inducible nuclear factors bind to an enhancer element located 3′ to the human erythropoietin gene. Proc Natl Acad Sci USA 1991; 88: 5680-5684.
22. Wang GL, Semenza GL. Characterization of hypoxia-inducible factor-1 and regulation of DNA binding activity by hypoxia. J Biol Chem 1993; 269: 21513-21518.
23. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992; 359: 843-845.
24. Levy AP, Levy NS, Goldberg MA. Hypoxia-inducible protein binding to vascular endothelial growth factor mRNA and its modulation by the von Hippel-Lindau protein. J Biol Chem 1996; 271: 25492-25497.
25. 2 in muscle cells in culture. Am J Physiol 1992; 262(3 Pt 1): C682-C690.
26. Graeber TG, Peterson JF, Tsai M, Minoca K, Fornace Jr AJ, Giaccia AJ. Hypoxia induces accumulation of p53 protein, but activation of a G1-phase checkpoint by low-oxygen conditions is independent of p53 status. Mol Cell Biol 1994; 14: 6263-6277.
27. Mazure NM, Eunice Y, Chen EY, Keith R, Laderoute KR, Amato JC. Giaccia Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-Kinase/Akt signalling pathway in Ha-Ras-transformed cells through a hypoxia inducible factor-1 transcriptional element. Blood 1997; 90: 3322 3331.
28. Melillo G, Taylor LS, Brooks A, Musso T, Cox GW, Varesio L. Functional requirement of the hypoxia-responsive element in the activation of the inducible nitric oxide synthase promoter by the iron chelator desferrioxamine. J Biol Chem 1997; 272: 12236-12243.
29. Comerford KM, Wallace TJ, Karhausen J, Louis NA, Montalto MC, Colgan SP. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res 2002; 62: 3387-3394.
30. Ryan HE, Lo J, Johnson RS. HIF-1α is required for solid tumour formation and embryonic vascularisation. EMBO J 1998; 17: 3005-3015.
31. Zhong H, de Marzo AM, Laughner E, et al. Overexpression of hypoxia-inducible factor-1α in common human cancers and their metastases. Cancer Res 1999; 59: 5830-5835.
32. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumours: a review. Cancer Res 1989; 49: 6449-6465.
33. Airley RE, Monaghan JE, Stratford IJ. Hypoxia and disease: opportunities for novel diagnostic and therapeutic prodrug strategies. The Pharm J 2000; 264: 666-673.
34. Brown JM. The hypoxic cell: a target for selective cancer therapy - Eighteenth Bruce F. Cain Memorial Award Lecture. Cancer Res 1999; 59: 5863-5870.
35. Folkman J. Tumour angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-1186.
36. Shweiki D, Neeman M, Itin A, Keshet E. Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: implications for tumour angiogenesis. Proc Natl Acad Sci USA 1995; 92: 768-772.
37. Pidgeon GP, Barr MP, Harmey JH, Foley DA, Bouchier-Hayes DJ. Vascular endothelial growth factor (VEGF) up regulates Bcl-2 and inhibits apoptosis in human and murine mammary adenocarcinoma cells. Br J Cancer 2001; 85: 273-278.
38. Minchenko A, Bauer T, Salceda S, Caro J. Hypoxic stimulation of vascular endothelial growth factor expression in vitro and in vivo. Lab Invest 1994; 71: 374-379.
39. Ikeda E, Achen MG, Breier G, Risau W. Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells. J Biol Chem 1995; 270: 19761-19766.
40. Shih SC, Claffey KP. Hypoxia-mediated regulation of gene expression in mammalian cells. Int J Exp Path 1998; 79: 347-357.
41. Royds JA, Dower SK, Qwarnstrom EE, Lewis CE. Response of tumour cells to hypoxia: role of p53 and NFkB. Mol Pathol 1998; 51: 55-61.
42. Lane DP, Lu X, Hupp T, Hall PA. The role of the p53 protein in the apoptotic response. Philos Trans R Soc Lond B Biol Sci 1994; 345: 277-280.
43. An WG, Kanekal M, Simon MC, Maltepe E, Blagosklonny MV, Neckers LM. Stabilization of wild-type p53 by hypoxia-inducible factor-1α. Nature 1998; 392: 405-408.
44. Graeber TG, Osmanian C, Jacks T, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996; 379: 88-91.
45. Kim CY, Tsai MH, Osmanian C, et al. Selection of human cervical epithelial cells that possess reduced apoptotic potential to low oxygen conditions. Cancer Res 1997; 57: 4200-4204.
46. Wang JH, Qiong DW, Bouchier-Hayes D, Redmond HP. Hypoxia up regulates Bcl-2 expression and suppresses interferon-γ induced anti-angiogenic activity in human tumour derived endothelial cells. Cancer 2002; 94: 2745-2755.
47. Warburg O. On the origin of cancer cells. Science 1956; 123: 309-314.
48. Schmaltz C, Hardenbergh PH, Wells A, Fisher DE. Regulation of proliferation-survival decisions during tumour cell hypoxia. Mol Cell Biol 1998; 18: 2845-2854.
49. Vaupel P, Schaefer C, Okunieff P. Intracellular acidosis in murine fibrosarcomas coincides with ATP depletion, hypoxia, and high levels of lactate and total Pi. NMR Biomed 1994; 7: 128-136.
50. 2 gradients in solid tumours in vivo high-resolution measurements reveal a lack of correlation. Nature 1997; 3: 177-182.
51. Sly WS, Hu PY. Human carbonic anhydrases and carbonic anhydrase deficiencies. Annu Rev Biochem 1995; 64: 375-401.
52. Wykoff CC, Beasley NJP, Watson PH, et al. Hypoxia-inducible expression of associated-associated carbonic anhydrase IX, in invasive breast carcinoma. Cancer Res 2000; 60: 7075-7083.
53. Gray LH, Conger AD, Ebert M, Hornsey S, Scott OC. Concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 1953; 26: 638-648.
54. Teicher BA, Lazo JS, Sartorelli AC. Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumour cells. Cancer Res 1981; 41: 73-81.
55. Laurence DR, Bennett PN, Brown MJ. Neoplastic disease and immunosuppression. Clinical Pharmacology 8 edn., New York: Churchill Livingstone, 1997; 545-563.
56. Teicher BA. Hypoxia and drug-resistance. Cancer Metast Rev 1994; 13: 139-168.
57. Teicher BA, Holden SA, Jacobs JL. Approaches to defining the mechanism of enhancement by Fluosol-DA20% with carbogen of melphalan anti-tumour activity. Cancer Res 1987; 47: 513-518.
58. Cunningham ML, Ringrose PS, Lokesh BR. Inhibition of the genotoxicity of bleomycin by superoxide dismutase. Mutat Res 1984; 135: 199-202.
59. Wozniak AK, Ross WE. DNA damage as a basis for 4′- dimethylepipodophyllotoxin-9- (4,6-O-ethylidene-β-D- glucopyranoside) (etoposide) cytotoxicity. Cancer Res 1983; 43: 120-124.
60. Wozniak AJ, Glisson BS, Hande KR, Ross WE. Inhibition of etoposide-induced DNA damage and cytotoxicity in L1210 cells by dehydrogenase inhibitors and other agents. Cancer Res 1984; 44: 626-632.
61. Amellem O, Pettersen EO. Cell inactivation and cell cycle inhibition as induced by extreme hypoxia: the possible role of cell cycle arrest as a protection against hypoxia-induced lethal damage. Cell Prolif 1991; 244: 127-141.
62. Gardner LB, Li Q, Park MS, Flanagan WM, Semenza GL, Dang CV. Hypoxia inhibits G1/S transition through regulation of p27 expression. J Biol Chem 2001; 276: 7919-7926.
63. Green SL, Freiberg RA, Giaccia AJ. p21 (Cip 1) and p27 (Kip1) regulate cell cycle reentry after hypoxic stressbut are not necessary for hypoxia-induced arrest. Mol Cell Biol 2001; 21: 1196-1206.
64. Rang HP, Dall MM, Ritter JM. In: Pharmacology. 4th edn. Churchill Livingstone: Edinburgh, 1999; 670-677.
65. Walker LJ, Craig RB, Harris AL, Hickson ID. A role for the human DNA-repair enzyme HAP1 in cellular-protection against DNA-damaging agents and hypoxic stress. Nucleic Acids Res 1994; 22: 4884-4889.
66. Murphy BJ, Laderoute KR, Chin RJ, Sutherland RM. Metallothionein IIA is up regulated by hypoxia in human A431 squamous carcinoma cells. Cancer Res 1994; 53: 5808-5810.
67. Ebert MP, Günther T, Hoffmann J, et al. Expression of metallothionein II in intestinal metaplasia, dysplasia, and gastric cancer. Cancer Res 2000; 60: 1995-2001.
68. Fardel O, Locureur V, Guilllouzo A. The P-glycoprotein multidrug transporter. Gen Pharmacol 1996; 27: 1283-1291.
69. Nooter K, Westerman AM, Flens MJ, et al. Expression of the multidrug resistance-associated protein (MRP) gene in human cancers. Clin Cancer Res 1995; 1: 1301-1310.
70. Rice GC, Ling V, Schimke RT. Frequencies of independent and simultaneous selection of Chinese hamster cells for methotrexate and doxorubicin (adriamycin) resistance. Proc Natl Acad Sci USA 1987; 84: 9261-9264.
71. Comerford KM, Wallace TJ, Karhausen J, Louis NA, Montalto MC, Colgan SP. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res 2002; 62: 3387-3394.
72. Sutherland RM. Cell and environment interactions in tumour microregions, the multicell spheroid model. Science 1988; 248: 177-184.
73. Tannock I. Response of aerobic and hypoxic cells in a solid tumour to adriamycin and cyclophosphamide and interaction of the drugs with radiation. Cancer Res 1982; 42: 4921-4926.
74. Durand RE. Distribution and activity of antineoplastic drugs in a tumour model. J Natl Cancer Inst 1989; 81: 146-152.
75. Teicher BA, Holden SA, Al-Achi A, Herman TS. Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumour subpopulation in vivo in the FSaIIC murine fibrosarcoma. Cancer Res 1990; 50: 3339-3344.
76. Skovsgaard T. Transport and binding of daunorubicin, Adriamycin and rubidazole in Ehrlich ascites tumour cells. Biochem Pharmacol 1977; 26: 215-222.
77. Brown JM. SR 4233 (tirapazamine): A new anticancer drug exploiting hypoxia in solid tumours. Br J Cancer 1993; 67: 1163-1170.
78. Siim BG, van Zijl PL, Brown JM. Tirapazamine-induced DNA damage measured using the comet assay correlates with cytotoxicity towards hypoxic tumour cells in vitro. Br J Cancer 1996; 73: 952-960.
79. Wang J, Biedermann KA, Brown JM. Repair of DNA and chromosome breaks in cells exposed to SR 4233 under hypoxia or to ionizing radiation. Cancer Res 1992; 52: 4473-4477.
80. Peters KB, Wang H, Brown JM, Iliakis G. Inhibition of DNA replication by Tirapazamine. Cancer Res 2001; 61: 5425-5431.
81. Peters KB, Brown JM. Tirapazamine: a hypoxia-activated topoisomerase II poison. Cancer Res 2002; 62: 5248-5253.
82. Rischin D, Peters L, Hicks R, et al. Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer. J Clin Oncol 2001; 19: 535-542.
83. Von Pawel J, von Roemeling R. Survival benefits from tirazone (tirapazamine) and cisplatin in advanced nonsmall lung cancer (NSCLC) patients: final results from the international Phase III CATAPULT1 trial. Proc Natl Acad Soc Clin Oncol 1998; 16: 3524-3527.
84. von Pawel J, von Roemeling R, Gatzemeier U, et al. Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group. Cisplatin and tirapazamine in subjects with advanced previously untreated non-small-cell lung tumours. J Clin Oncol 2000; 18: 1351-1359.
85. Rapisarda A, Uranchimeg B, Scudiero DA, et al. Identification of small molecule inhibitors of hypoxia-inducible factor-1 transcriptional activation pathway. Cancer Res 2002; 62: 4316-4324.
86. Kung AL, Wang S, Klco JM, Kaelin WG, Livingston DM. Suppression of tumour growth through disruption of hypoxia-inducible transcription. Nat Med 2000; 6: 1335-1340.
87. Sun X, Kanwar JR, Leung E, Lehnert K, Wang D, Krissansen GW. Gene transfer of antisense hypoxia-inducible factor-1α enhances the therapeutic efficacy of cancer immunotherapy. Gene Ther 2001; 8: 638-645.
88. Dachs GU, Dougherty GJ, Stratford IJ, Chaplin DJ. Targeting gene therapy to cancer: a review. Oncol Res 1997; 9: 313-325.
89. Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 2002; 196: 254 265.
90. Van Ravensway, Claasen HH, Kluin PM, Fleuren GJ. Tumour infiltrating cells in human cancer. On the possible role of CD16+ macrophages in anti-tumour cytotoxicity. Lab Invest 1992; 67: 166-174.
91. Stephens TC, Currie GA, Peacock JH. Repopulation of gamma-irradiated Lewis lung carcinoma by malignant cells and host macrophage progenitors. Br J Cancer 1978; 38: 572-582.
92. Leek RD, Landers RJ, Harris AL, Lewis CE. Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast. Br J Cancer 1999; 79: 991-995.
93. Negus RP, Turner L, Burke F, Balkwill FR. Hypoxia down-regulates MCP-1 expression: omplications for macrophage distribution in tumours. J Leukoc Biol 1998; 63: 758-765.
94. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis Lung carcinoma. Cell 1994; 79: 315-328.
95. Claesson-Welsh L, Welsh M, Ito N, et al. Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD. Proc Natl Acad Sci USA 1998; 95: 5579-5583.
96. Griffiths L, Binley K, Iqball S, et al. The macrophage - a novel system to deliver gene therapy to pathological hypoxia. Gene Ther 2000; 7: 255-262.
97. Krantz SB. Erythropoietin. Blood 1991; 77: 419-434.
98. Lin CS, Lim SK, D'Agati V, Costantini F. Differentiatial effects of an erythropoietin receptor gene disruption on primitive and definitive erythropoiesis. Genes Dev 1996; 10: 154-164.
99. Jelkmann W. Erythropoietin: structure, control of production, and function. Physiol Rev 1992; 72: 449-489.
100. Lacombe C, Mayeux P. Biology of erythropoietin. Haematologica 1998; 83: 724-732.
101. Goldberg MA, Gaut CC, Bunn HF. Erythropoietin mRNA levels are governed by both the rate of gene transcription and post-transcriptional events. Blood 1991; 77: 271-277.
102. Youssoufian H, Longmore G, Neumann D, Yoshimura A, Lodish HF. Structure, function, and activation of the erythropoietin receptor. Blood 1993; 81: 2223-2236.
103. Cosman D. The hematopoietin receptor superfamily. Cytokine 1993; 5: 95-106.
104. Dicato M, Duham C, Berchem G, Ries F. Clinical benefit from erythropoietin. Curr Opin Oncol 2000; 12: 297-302.
105. Kelleher DK, Mattheinsen U, Thews O, Vaupel P. Blood flow, oxygenation, and bioenergetic status of tumours after erythropoietin treatment in normal and anemic rats. Cancer Res 1996; 56: 4728-4734.
106. Birgegard G, Sandhagen B. Erythropoietin treatment can increase 2,3-diphosphoglycerate levels in red blood cells. Scand J Clin Lab Invest 2001; 61: 337-340.
107. Thews O, Kelleher DK, Vaupel P. Erythropoietin restores the anemia-induced reduction in cyclophosphamide cytotoxicity in rat tumours. Cancer Res 2001; 61: 1358-1361.
108. Silver DF, Piver MS. Effects of recombinant human erythropoietin on the anti-tumour effect of cisplatin in SCID mice bearing human ovarian cancer: a possible oxygen effect. Gynecol Oncol 1999; 73: 280-284.
109. Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer 2001; 84(Suppl 1): 3-10.
110. Momerency G, Van Cauwenberghe K, Highley MS, Harper PG, Van Oosterom AT, de Bruijn EA. Partitioning of ifosfamide and its metabolites between red blood cells and plasma. J Pharm Sci 1996; 85: 262-265.
111. Mittelman M, Neumann D, Peled A, Kanter P, Haran-Ghera N. Erythropoietin induces tumour regression and anti-tumour immune responses in murine myeloma models. Proc Natl Acad Sci USA 2001; 98: 5181-5186.
112. Westenfelder C, Baranowski RL. Erythropoietin stimulates proliferation of human renal carcinoma cells. Kidney Int 2000; 58: 647-657.
113. Juul SE, Yachnis AT, Rojiani AM, Christiansen RD. Immunohistochemical localization of erythropoietin and its receptor in the developing human brain. Pediatr Dev Pathol 1999; 2: 148-158.
114. Juul SE, Zhao Y, Dame JB, Du Y, Hutson AD, Christiansen RD. Origin and fate of erythropoietin in human milk. Pediatr Dev Pathol 2000; 48: 660-667.
115. Yasuda Y, Masuda S, Chikuma M, Inoue K, Nagao M, Sasaki R. Estrogen-dependent production of erythropoietin in uterus and its implication in uterine angiogenesis. J Biol Chem 1998; 273: 25381-25387.
116. Acs G, Acs P, Beckwith SM, et al. Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res 2001; 61: 3561-3565.
117. del Peso G, Selgas R, Bajo MA, et al. Serum level of vascular endothelial growth factor is influenced by erythropoietin treatment in peritoneal dialysis patients. Adv Perit Dial 2000; 16: 85-89.
118. Eatock MM, Schatzlein A, Kaye SB. Tumour vasculature as a target for anticancer therapy. Cancer Treat Rev 2000; 26: 191-204.
119. Harmey JH, Bouchier-Hayes DJ. Vascular endothelial growth factor, a survival factor for tumour cells: implications for antiangiogenic therapy. BioEssays 2002; 24: 280-283.
120. Lee CG, Heijn M, Di Tomaso E, et al. Anti-vascular endothelial growth factor treatment augments tumour radiation response under normoxic or hypoxic conditions. Cancer Res 2000; 60: 5565-5570.
121. Morin MJ. From oncogene to drug: development of small tyrosine kinase inhibitors as anti-tumour and anti-angiogenic agents. Oncogene 2000; 19: 6574-6583.
122. Liau G, Su EJ, Dixon KD. Clinical efforts to modulate angiogenesis in the adult: Gene therapy versus conventional approaches. Drug Disc Today 2001; 6: 689-697.
123. Dvorak HF, Nagy JA, Feng D, Brown LF, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr Top Microbiol Immunol 1999; 237: 97-131.
124. Netti PA, Hamberg LM, Babich JW, et al. Enhancement of fluid filtration across tumour vessels: implication for delivery of macromolecules. Proc Natl Acad Sci USA 1999; 96: 3137-3142.